GSK vet named CEO of Chi­na CAR-T JV with Kite; Co­herus fights back against Am­gen claims it stole trade se­crets

→ Richard Wang, the for­mer site chief for GSK in Shang­hai, is tak­ing the CEO’s job at Fo­s­un Kite, a joint ven­ture es­tab­lished by Kite Phar­ma and Shang­hai Fo­s­un to ad­vance Kite’s CAR-T $KITE to the mar­ket.

→Am­gen $AMGN has filed a law­suit against Co­herus Bio­Sciences $CHRS claim­ing theft of trade se­crets, ac­cord­ing to a state­ment from the biotech. And the Red­wood City, CA-based Co­herus says it plans to de­fend it­self vig­or­ous­ly, adding that Am­gen is sole­ly in­ter­est­ed in fend­ing off com­pe­ti­tion to peg­fil­gras­tim by mount­ing a de­lay­ing ac­tion in state court. “Co­herus re­mains com­mit­ted to the im­por­tant goal of bring­ing much-need­ed biosim­i­lar drugs to the mar­ket­place,” said CEO Den­ny Lan­fear in a state­ment. “We are con­fi­dent that we will pre­vail in this ac­tion and achieve our goals of in­creas­ing pa­tient ac­cess, in­tro­duc­ing com­pe­ti­tion and of­fer­ing biosim­i­lar prod­ucts at prices com­pet­i­tive with and low­er than those main­tained by Am­gen and oth­er large phar­ma­ceu­ti­cal com­pa­nies.”

Ralph Kern, Brain­storm Cell Ther­a­peu­tics

→ Is­rael’s Brain­storm Cell Ther­a­peu­tics has re­cruit­ed a top sci­en­tist from Bio­gen. Ralph Kern has been named chief med­ical of­fi­cer of the biotech, which is work­ing on adult stem cell ther­a­pies for neu­rode­gen­er­a­tive dis­eases. Brain­storm is prep­ping for a Phase III in ALS.

→ San­ford Health has in­vest­ed $20 mil­lion in In­Gen­eron, a Hous­ton-based re­gen­er­a­tive med­i­cine com­pa­ny. “This sig­nif­i­cant in­vest­ment demon­strates San­ford’s com­mit­ment to be an ac­tive par­tic­i­pant in In­Gen­eron as well as be­ing our clin­i­cal tri­al site of choice,” said Ron Stub­bers, MBA, Pres­i­dent of In­Gen­eron. “Our joint ef­forts will en­able the com­pa­ny to make re­gen­er­a­tive cell ther­a­pies avail­able to clin­i­cal prac­tice and to es­tab­lish a lead­ing po­si­tion in the ap­pli­ca­tion of adi­pose-de­rived re­gen­er­a­tive cells.”

→ Ver­nalis and Servi­er have struck a new two-year dis­cov­ery col­lab­o­ra­tion fo­cused on on­col­o­gy. Ver­nalis has scored €2 mil­lion up­front along with fees and mile­stones to go to work seek­ing new drugs for Servi­er. “This new col­lab­o­ra­tion fur­ther val­i­dates our frag­ment-based drug dis­cov­ery plat­form and the strength and suc­cess of our re­la­tion­ship with Servi­er.  We look for­ward to work­ing to­geth­er to de­vel­op ex­cit­ing new can­cer treat­ment op­por­tu­ni­ties to add to the al­ready dis­closed suc­cess in tar­get­ing Bcl-2 and Mcl-1”, com­ment­ed Ian Gar­land, CEO of Ver­nalis.

→ Boehringer In­gel­heim is at work on a new col­lab­o­ra­tion with Van­der­bilt Uni­ver­si­ty, fo­cus­ing on the re­search and de­vel­op­ment of small mol­e­cule com­pounds tar­get­ing the pro­tein SOS (Son Of Sev­en­less). “This mol­e­cule ac­ti­vates KRAS, a mol­e­c­u­lar switch that plays a cen­tral role in the on­set of some of the dead­liest can­cers.”

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

The Avance Clinical leadership team: CEO Yvonne Lungershausen, Sandrien Louwaars - Director Business Development Operations, Gabriel Kremmidiotis - Chief Scientific Officer, Ben Edwards - Chief Strategy Officer

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

About Avance Clinical

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services to the local and international drug development industry for 20 years. They specialise in working with biotech companies to execute Phase 1 and Phase 2 clinical trials to deliver high-quality outcomes fit for global regulatory standards.

As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.

As­traZeneca trum­pets the good da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

Dan O'Day, Gilead CEO (Andrew Harnik, AP Images)

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash for the buy-in plus equity, along with $400 million for R&D and $1.22 billion in reserve to cover opt-in payments and milestones..

Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab. O’Day also has first dibs on TIGIT and 2 other leading programs, agreeing to an opt-in fee ranging from $200 million to $275 million on each. There’s $500 million in potential TIGIT milestones on US regulatory events — likely capped by an approval — if Gilead partners on it and the stars align on the data. And there’s another $150 million opt-in payments for the rest of the Arcus pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis jumps in­to Covid-19 vac­cine hunt, as Big Phar­ma and big biotech com­mit to bil­lions of dos­es

After spending most of the pandemic on the sidelines, Novartis is offering its aid in the race to develop a Covid-19 vaccine.

AveXis, the Swiss pharma’s gene therapy subsidiary, has agreed to manufacture the vaccine being developed by Massachusetts Eye and Ear and Massachusetts General Hospital. The biotech will begin manufacturing this month, while the vaccine undergoes further preclinical testing. They’ve agreed to provide the vaccine for free for clinical trials beginning in the second half of 2020, but have not disclosed financials for after.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

Bryan Roberts, Venrock

Ven­rock sur­vey shows grow­ing recog­ni­tion of coro­n­avirus toll, wan­ing con­fi­dence in ar­rival of vac­cines and treat­ments

When Venrock partner Bryan Roberts went to check the results from their annual survey of healthcare leaders, what he found was an imprint of the pandemic’s slow arrival in America.

The venture firm had sent their form out to hundreds of insurance and health tech executives, investors, officials and academics on February 24 and gave them two weeks to fill it out. No Americans had died at that point but the coronavirus had become enough of a global crisis that they included two questions about the virus, including “Total U.S. deaths in 2020 from the novel coronavirus will be:”.

Roger Perlmutter, Merck R&D chief (YouTube)

UP­DAT­ED: Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Merck execs are making a triple play in a sudden leap into the R&D campaign against Covid-19. And they have more BARDA cash backing them up on the move.

Tuesday morning the pharma giant simultaneously announced plans to buy an Austrian biotech that has been working on a preclinical vaccine candidate, added a collaboration on another vaccine with the nonprofit IAVI and inked a deal with Ridgeback Biotherapeutics on an early-stage antiviral.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

Stymied by the pan­dem­ic, Im­munomedic­s' new CEO bows out, tak­ing a mil­lion bucks plus perks as he heads out the vir­tu­al ex­it

Just a little more than a month since taking over as the latest CEO to helm Immunomedics, $IMMU Harout Semerjian is exiting the company after being confronted by “logistical” obstacles thrown up by the pandemic that made it impossible for him to move from London to carry out the job. And he’s getting a little over a million dollars in cash plus perks to grease the skids on the way out.

Word of the changeup arrived right after the market closed Wednesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.